{"a":[{"_":"Attovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPO","$":{"href":"/biotech/attovia-aims-scratch-itch-opportunity-and-challenge-dupixent-289m-ipo","hreflang":"en"}}]}

Summary

Attovia Therapeutics raised $289 million in its IPO to advance anti-itch drug candidates through clinical development, positioning itself as a competitor to Regeneron's Dupixent in the dermatology market.